Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Genomic Health Test to Guide Chemo Per New Breast Cancer Rule
by Zacks Equity Research
This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk
by Zacks Equity Research
With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
Here's Why You Should Add Stryker (SYK) to Your Portfolio
by Zacks Equity Research
Stryker (SYK) gains from core segments in the second quarter of 2019.
Restoration Robotics (HAIR) Wins CE Mark for ARTAS iX System
by Zacks Equity Research
This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.
Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.
BAX vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) raises the revenue guidance for fiscal 2019.
Walgreens (WBA) Expands Partnership With Retail Giant Kroger
by Zacks Equity Research
The extended partnership deal with Kroger will help Walgreens (WBA) strengthen its market presence.
Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.
Here's Why You Should Invest in DaVita (DVA) Stock For Now
by Zacks Equity Research
DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.
Here's Why You Should Retain Nevro (NVRO) in Your Portfolio
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Here's Why You Should Retain Wright Medical Stock For Now
by Zacks Equity Research
Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.
Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod
by Zacks Equity Research
Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.
Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Omnicell's (OMCL) prospects.
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
by Zacks Equity Research
The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.
Here's Why You Should Snap Up Baxter International (BAX) Now
by Zacks Equity Research
For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.
Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.
The Zacks Analyst Blog Highlights: Deere, Baxter, EPAM Systems, NiSource and Universal Display
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Deere, Baxter, EPAM Systems, NiSource and Universal Display
Baxter's PrisMax Adopted by Hamilton Health Care System
by Zacks Equity Research
Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.
Top Analyst Reports: Deere, Baxter & More
by Mark Vickery
Today's Research Daily features updated research reports on 11 major stocks, including Deere (DE) and Baxter (BAX).
CVS Health Banks on Health Care Benefit Prospects Amid Woes
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.
Here's Why You Should Hold Onto Insulet (PODD) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Insulet's (PODD) solid prospects.